TamaFlex
TamaFlex, licence 80089961: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- NXT USA, Inc.
- NPN or DIN-HM
- 80089961
- Status
- Active licence
- Licence date
- 7 January 2019
- Revision date
- 27 January 2025
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Curcuma longa Source : Rhizome Extract : Matériel brut sec Extraction ratio : 7-12:1.0 Dry plant equivalent : 105-180 milligramme Potency : 15.0 % Curcuminoids | 15.0 milligramme | Not calculated |
| Tamarindus indica Source : Graine(s) Extract : Matériel brut sec Extraction ratio : 8-12:1.0 Dry plant equivalent : 240-360 milligramme Potency : 90.0 % Proanthocyanidins | 30.0 milligramme | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Hypromellose, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 1.0 Capsule ; maximum: 4.0 Capsule | minimum: 1.0 Jour(s) ; maximum: 2.0 Jour(s) |
Uses authorised in Canada
Text supplied in English because no French text is available.
Source of antioxidant(s)/Provides antioxidant(s). Source of antioxidant(s)/Provides antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Provides antioxidants for the maintenance of good health. Helps to improve joint health by reducing knee joint pain, knee joint stiffness and improving physical function associated with daily physical activity/mild to moderate osteoarthritis of the knee. Helps to reduce/relieve knee joint pain associated with daily physical activity/mild to moderate osteoarthritis of the knee. Helps to reduce knee stiffness associated with daily physical activity/mild to moderate osteoarthritis of the knee. Helps to promote joint comfort associated with daily physical activities/mild to moderate osteoarthritis of the knee. Helps to promote joint movement and physical functioning associated with daily physical activity/mild to moderate osteoarthritis of the knee by reducing joint pain and stiffness. Helps to improve ability to perform daily activities by reducing joint stiffness. Helps relieve joint pain associated with daily physical activity in 14 days. Helps relieve joint pain associated with mild to moderate osteoarthritis of the knee in 5 days. Clinically proven to provide relief from joint stiffness/pain associated with mild to moderate osteoarthritis of the knee in as little as 5 days. Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation associated with osteoarthritis of the knee. Helps reduce levels of CTX-II, a biomarker/marker of joint degradation associated with osteoarthritis of the knee. Helps to reduce blood C reactive protein levels, a clinical marker of inflammation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use if you are pregnant, have gallstones, a bile duct obstruction, stomach ulcers, excess stomach acid, if symptoms persist or worsen, or for use beyond 3 months.
Source
Official Health Canada record, licence 80089961
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.